基于酸的蛋白质药物的持续释放系统
Kosei Utatsu1, Keiichi Motoyama1, Teruya Nakamura1
1Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan.
International journal of pharmaceutics
|July 16, 2023
概括
酸形成不溶性蛋白质药物沉物,用于持续释放. 这种简单的药物输送系统维持了蛋白质的活性并增强了治疗效果,为蛋白质治疗提供了一个用户友好的方法.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 蛋白质治疗药物 蛋白质治疗药物
背景情况:
- 蛋白质药物开发需要简单,有效的控制释放系统.
- 现有的方法可能导致蛋白质变性或活性丧失.
- 需要易于和稳定的蛋白质药物输送平台.
研究的目的:
- 开发一种简单有效的蛋白质药物持续释放系统.
- 研究酸用于蛋白质药物复合和受控释放的用途.
- 评估蛋白质-酸复合物的活性和有效性.
主要方法:
- 利用酸的收缩机制,与各种蛋白质药物形成不溶性沉物.
- 描述了酸与蛋白质 (尼辛,胰岛素,溶酶,卵,氨酸酶,IgG) 之间的相互作用 (疏水性,键).
- 评估了体外活性 (lyszyme),体内疗效 (胰岛素的低血糖效应) 和免疫性 (卵胺的抗体产生).
主要成果:
- 酸成功地与多种蛋白质药物形成不溶性沉物.
- 酶/酸复合物保持了其在体外的酸活性.
- 胰岛素/酸复合物在给药后表现出持续的低血糖效应,卵/酸复合物增强了抗体的产生.
结论:
- 酸作为蛋白质药物的简单和用户友好的药物输送系统.
- 酸介导沉方法对持续的蛋白质释放有效,而不会影响活性.
- 这种方法有望改善基于蛋白质的药物的治疗结果.
相关概念视频
Drug Distribution: Tissue Binding
2.7K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.7K
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
298
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
298
Drug Delivery: Overview
326
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
326
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
231
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
231
Drug Distribution: Plasma Protein Binding
5.7K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.7K
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
212
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
212


